Schering Corporation

Merck Sharp + Dohme Corp.

Andrew Joseph Prongay

Vincent Stewart Madison

Paul Reichert

Li Xiao

Tin-Yau Chan

Thierry Olivier Fischmann

Brian M Beyer

Richard N Ingram

Viyyoor Moopil Girijavallabhan

Ashit K Ganguly

Brian Alexander McKittrick

Ashok Arasappan

Srikanth Venkatraman

Kevin X Chen

Alan W Hruza

William T Windsor

Nanhua Hugh Yao

Todd W Mayhood

Haiyan Pu

Chandra C Kumar

Joseph E Myers

Rosalinda Syto

Mark A McCoy

F George Njoroge

Anil K Saksena

Hung V Le

Edwin Jao

Bancha Vibulbhan

Tejal Parekh

Thomas E Hesson

Krishna Kalghatgi

Li Wang

George F Njoroge

Liwu Hong

Jennifer Joanne Gesell

Brian Alexander Mc Kittrick

Haining Gu

Michael R Ziebell

The present invention relates to factor IXa complexes and crystals thereof as well as methods for identifying inhibitors of factor IXa.

Factor IXa crystals, related complexes and methods

The present invention provides methods for identifying modulators of PCSK9, for example, using a variety of assay formats. Inhibitors of PCSK9 can be used for example, to treat diseases such as hyperlipidemia and related disorders.

Assay for PCSK9 inhibitors

The present invention provides, in part, AKT3 polypeptides and methods of use thereof along with nucleic acids encoding the polypeptides. For example, methods for screening for AKT3 inhibitors are provided herein.

Kinase domain polypeptide of human protein kinase B gamma (AKT3)

Polynucleotides encoding polypeptide fragments of protein kinase B gamma (AKT3)

Disclosed is a compound of the formula: and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating protein kinase mediated diseases using the compound of formula 1.0. Also disclosed are methods of treating cancer using a compound of formula 1.0. The disclosed methods also include combination therapies wherein the compound of formula 1.0 is administered in combination with at least one addition pharmaceutically active ingredient.

Substituted indazoles of formula 1.0 that are kinase inhibitors

A compound having the general structure of Formula (I): or a pharmaceutically acceptable salt, solvate, or ester thereof, are useful in treating diseases, disorders, or conditions such as immunodeficiencies, cancers, cardiovascular diseases, endocrine disorders, Parkinson's disease, metabolic diseases, tumorigenesis, Alzheimer's disease, heart disease, diabetes, neurodegeneration, inflammation, kidney disease, atherosclerosis and airway disease.

Kinase inhibitors

The present invention discloses novel macrocyclic compounds which have HCV protease inhibitory activity as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising such macrocycles as well as methods of using them to treat disorders associated with the HCV protease.

Macrocyclic NS-3 serine protease inhibitors of hepatitis C virus comprising alkyl and aryl alanine P2 moieties

Macrocyclic NS3-serine protease inhibitors of hepatitis C virus comprising N-cyclic P2 moieties

Growing community of inventors

Billerica, MA, United States of America

Andrew Joseph Prongay